CSIMarket
 
Mereo Biopharma Group Plc  (MREO)
Other Ticker:  
 
 
Price: $3.0900 $-0.02 -0.643%
Day's High: $3.135 Week Perf: -11.71 %
Day's Low: $ 2.99 30 Day Perf: -16.26 %
Volume (M): 823 52 Wk High: $ 4.36
Volume (M$): $ 2,543 52 Wk Avg: $1.86
Open: $3.03 52 Wk Low: $0.69



 Market Capitalization (Millions $) 1,761
 Shares Outstanding (Millions) 570
 Employees 46
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) 94
 Capital Exp. (TTM) (Millions $) 0

Mereo Biopharma Group Plc
Mereo Biopharma Group Plc is a UK-based clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics for rare and specialty diseases. The company is dedicated to developing therapies that have the potential to transform the lives of patients affected by diseases that currently have limited or no treatment options. Mereo Biopharma aims at commercializing these therapies through partnerships or in-house efforts.

Mereo Biopharma has a diversified pipeline of clinical-stage product candidates that range from rare metabolic disorders to oncology. The company's lead program is setrusumab, which is in Phase 3 development for osteogenesis imperfecta, a rare genetic bone disorder. The company also has an active clinical program in the treatment of Alport syndrome, a rare genetic kidney disease. Additionally, the company is developing navicixizumab, which is in Phase 1b/2a development for the treatment of cancers with high unmet medical needs, such as pancreatic and ovarian cancers.

Mereo Biopharma has a strong track record of partnering with leading pharmaceutical companies to advance its pipeline programs to commercialization. The company has formed collaborations with Novartis, Oncomed, and Ultragenyx Pharmaceutical, among others.

Mereo Biopharma was founded in 2015 and is headquartered in London, UK, with offices in the US and Europe. The company has a dedicated team of experienced professionals who have extensive expertise in drug development and commercialization. Mereo Biopharma has a market capitalization of approximately e45 million as of June 202

In summary, Mereo Biopharma is a clinical-stage biopharmaceutical company that aims to address unmet medical needs by developing innovative therapies for rare and specialty diseases. The company has a diversified pipeline of clinical-stage product candidates, a successful partnering strategy, and a talented team of professionals dedicated to transforming the lives of patients through cutting-edge therapeutics.


   Company Address: One Cavendish Place London 0
   Company Phone Number: 333-023-7300   Stock Exchange / Ticker: NASDAQ MREO
   MREO is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Mereo BioPharma Sets Pace for 2024: Eyes Completion of Key Clinical Trials and Exciting Pipeline Developments.

Published Mon, Jan 8 2024 12:02 PM UTC

Mereo BioPharma, a leading biopharmaceutical company with the chief aim to develop and commercialize innovative therapeutics, has recently provided an update on its formidable pipeline progress and corporate developments. Mereo is setting significant milestones with its strategic focus on rare diseases with the potential to transform the life of patients globally. The compan...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com